News Briefs

摘要

1. FDA in June cleared the CoaguSense PT/INR monitoring system for at-home use by patients who have a prescription for the device and are stabilized on their oral anticoagulant therapy. According to manufacturer CoaguSense Inc., the device is the first one intended for use by patients to directly measure prothrombin time through "micromechanical" blood-clot detection and calculate the International Normalized Ratio.